A Randomized, Double-Blind, Placebo Controlled, Fixed Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia (SD-809-C-23)
|Effective start/end date||11/1/14 → 10/31/15|
- AUSPEX PHARMACEUTICALS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.